中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
阿糖胞苷 | arabinosyl cytosine | 147-94-4 | C9H13N3O5 | 243.219 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | (3S)-3-[[2-[[(2S)-2-(decanoylamino)-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(2S)-1-[[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid | 1223438-46-7 | C36H60N10O12 | 824.932 |
—— | (3S)-3-[[2-[[(2S)-5-(diaminomethylideneamino)-2-(dodecanoylamino)pentanoyl]amino]acetyl]amino]-4-[[(2S)-1-[[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid | 1223438-49-0 | C38H64N10O12 | 852.986 |
—— | (3S)-3-[[2-[[(2S)-5-(diaminomethylideneamino)-2-(tetradecanoylamino)pentanoyl]amino]acetyl]amino]-4-[[(2S)-1-[[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid | 1223438-53-6 | C40H68N10O12 | 881.04 |
—— | (3S)-3-[[2-[[(2S)-5-(diaminomethylideneamino)-2-(hexadecanoylamino)pentanoyl]amino]acetyl]amino]-4-[[(2S)-1-[[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid | 1223438-56-9 | C42H72N10O12 | 909.093 |
—— | (3S)-3-[[2-[[(2S)-5-(diaminomethylideneamino)-2-(octanoylamino)pentanoyl]amino]acetyl]amino]-4-[[(2S)-1-[[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid | 1223438-44-5 | C34H56N10O12 | 796.878 |
本研究旨在探讨l-缬氨酰-阿糖胞苷(ara-C)的类肽前药在胃肠道稳定性和细胞摄取特性方面的表现。通过将l-缬氨酸引入ara-C 的胞嘧啶环的N4-氨基基团中,合成了l-缬氨酰-ara-C。使用人工胃液和人工肠液检测了l-缬氨酰-ara-C的胃肠道稳定性。在Caco-2细胞中,也检测了l-缬氨酰-ara-C的细胞摄取特性。在人工胃液中,l-缬氨酰-ara-C的消失半衰期为2.2小时,而在人工肠液和Caco-2细胞单层上方的上清液中,l-缬氨酰-ara-C的降解可以忽略不计。在Caco-2细胞中,l-缬氨酰-ara-C的细胞积累量比ara-C高5倍。此外,l-缬氨酰-ara-C的细胞摄取量并未与药物浓度成比例增加。在脲、对氨基苯甲酸、四乙基铵和小肽存在时,l-缬氨酰-ara-C的细胞积累量显著降低,而在l-缬氨酸和苯甲酸存在时则未发生变化,这表明l-缬氨酰-ara-C可能与多种摄取转运体相互作用,包括肽转运体、有机阴离子和阳离子转运体以及核苷转运体,但可能不与氨基酸转运体相互作用。总之,通过载体介导的转运途径,l-缬氨酰-ara-C可能有效提高ara-C的口服吸收。
This study aimed to investigate the gastrointestinal stability and the cellular uptake characteristics of l-valyl-ara-C, a peptidomimetic prodrug of ara-C (cytarabine). After the synthesis of l-valyl-ara-C via the incorporation of l-valine into the N4-amino group of the cytosine ring in ara-C, the gastrointestinal stability of l-valyl-ara-C was examined using artificial gastric juice and artificial intestinal fluids. The cellular uptake characteristics of l-valyl-ara-C were also examined in Caco-2 cells. The disappearance half-life of l-valyl-ara-C was 2.2 h in artificial gastric juice, while the degradation of l-valyl-ara-C was negligible in artificial intestinal fluid and also in the supernatant above the Caco-2 cell monolayer during the 2-h incubation. The cellular accumulation of l-valyl-ara-C was 5-fold higher than that of ara-C in Caco-2 cells. Furthermore, the cellular uptake of l-valyl-ara-C did not increase proportionally to the increase in drug concentration. The cellular accumulation of l-valyl-ara-C was significantly reduced in the presence of uridine, p-aminohippurate, tetraethylammonium and small dipeptides, while it was not changed in the presence of l-valine and benzoic acid, suggesting that l-valyl-ara-C could interact with multiple uptake transporters, including peptide transporters, organic anion and cation transporters and nucleoside transporters, but might not interact with amino acid transporters. In conclusion, l-valyl-ara-C could be effective to improve the oral absorption of ara-C via the carrier-mediated transport pathway.
本研究旨在探讨l-缬氨酰-阿糖胞苷(ara-C)的类肽前药在胃肠道稳定性和细胞摄取特性方面的表现。通过将l-缬氨酸引入ara-C 的胞嘧啶环的N4-氨基基团中,合成了l-缬氨酰-ara-C。使用人工胃液和人工肠液检测了l-缬氨酰-ara-C的胃肠道稳定性。在Caco-2细胞中,也检测了l-缬氨酰-ara-C的细胞摄取特性。在人工胃液中,l-缬氨酰-ara-C的消失半衰期为2.2小时,而在人工肠液和Caco-2细胞单层上方的上清液中,l-缬氨酰-ara-C的降解可以忽略不计。在Caco-2细胞中,l-缬氨酰-ara-C的细胞积累量比ara-C高5倍。此外,l-缬氨酰-ara-C的细胞摄取量并未与药物浓度成比例增加。在脲、对氨基苯甲酸、四乙基铵和小肽存在时,l-缬氨酰-ara-C的细胞积累量显著降低,而在l-缬氨酸和苯甲酸存在时则未发生变化,这表明l-缬氨酰-ara-C可能与多种摄取转运体相互作用,包括肽转运体、有机阴离子和阳离子转运体以及核苷转运体,但可能不与氨基酸转运体相互作用。总之,通过载体介导的转运途径,l-缬氨酰-ara-C可能有效提高ara-C的口服吸收。